Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006
- Valerie A Harpin, Ryegate Childrens Centre, Sheffield Children’s NHS Foundation Trust, Tapton Crescent Road, Sheffield S10 5DD, UK; val.harpin{at}sch.nhs.uk
- Accepted 3 January 2008
Abstract
In recent years the medication options for the treatment of ADHD in children and young people have increased. The National Institute for Health and Clinical Excellence (NICE) produced updated guidelines in 2006. This paper aims to interpret these guidelines by reviewing the medication options in light of relevant research and clinical practice. The properties of methylphenidate, dexamfetamine and atomoxetine are discussed.
Footnotes
-
Competing interests: The author has received a research grant from Eli Lilly, has acted as consultant on advisory boards for Jansen and UCB and has spoken at sponsored meetings.
